The effect of conjugated linoleic acid on oxidative stress and matrix metalloproteinases 2 and 9 in patients with COPD
What this study found
CLA supplementation produced favorable biomarker changes in COPD. MDA decreased from 0.23±0.10 to 0.15±0.13 nmol/ml (p=0.0004), and MMP9 decreased from 827±113 to 735±104 ng/ml, with significant between-group and within-group end-of-treatment differences reported (p=0.00; p=0.001 vs baseline for supplement and placebo comparisons). MMP2 did not change significantly, decreasing only from 986.27±108 to 980.33±100 ng/ml (p=0.11). Overall, the authors concluded that CLA may help COPD patients by inhibiting oxidative stress and controlling serum MMP9.
- Study & population
- This was a double-blind, randomized, placebo-controlled trial in adults with chronic obstructive pulmonary disease (COPD) treated at Imam Khomeini Hospital in Ardabil, Iran.
- Intervention
- The active intervention was oral conjugated linoleic acid (CLA) softgel capsules, 3.2 g daily for 6 weeks.
- Key limitation
- The trial was short, lasted only 6 weeks, and was conducted at a single center, which limits generalizability.
View source
Open PDFOriginal abstract
Background Natural antioxidants in foods may be used in prevention and treatment of oxidative stress and inflammation in COPD. Therefore, this study aimed to evaluate the effect of conjugated linoleic acid (CLA) supplement as natural antioxidants on oxidative stress levels, and MMP2 and MMP9 serum levels in COPD patients. Materials and methods This clinical trial study was conducted on 90 (supplement group=45 and control group=45) COPD patients in Ardabil city, Iran, in 2015. After obtaining written consent, general information was collected from each patient using a validated and reliable questionnaire. Supplement group received 3.2 g of CLA and those in the control group were given 3.2 g of placebo for 6 weeks on a daily basis. Fasting blood samples were taken from all of the patients for testing of malondialdehyde (MDA), MMP2, and MMP9 levels at the beginning and end of the study. Data were analyzed using Kolmogorov–Smirnov test, independent samples t-test, paired sample t-test, chi-square test, and ANOVA. Results There were no significant differences between the two groups with regard to mean age, smoking status, and serum level of MDA at the beginning of the study. In the supplement group, the serum level of MDA decreased significantly at the end of the 6th week compared to that in the beginning of the study (p=0.0004), while in the placebo group, the difference was found to be insignificant. The serum level of MMP9 decreased significantly in the supplement group, while in the placebo group its level increased significantly as compared to that at the beginning of the study (p<0.05). The serum levels of MMP2 indicated no significant differences between the two groups neither at the beginning nor at the end of the study. Conclusion These findings indicated that CLA supplementation may be helpful for COPD patients through inhibiting the production of oxidative stress and controlling MMP9 serum levels.